Skip Navigation

Wharton Laboratory

The Wharton Laboratory is focused on Alzheimer’s prevention and investigates the influence of midlife vascular risk factors on Alzheimer's disease (AD) in mostly cognitively normal populations. We develop observational & clinical trials in hopes of reducing Alzheimer's disease in people most at risk, including individuals with a parental history of AD, African Americans, family caregivers, women and the LGBTQ community.

Dr. Whitney Wharton, PhD, holds a dual appointment with Emory School of Medicine’s Cognitive Neurology Department and Emory’s School of Nursing.

Areas of investigation include:

  • Understanding the contribution of midlife vascular risk factors in AD and developing interventions to target the most relevant AD biomarkers including AD-related brain changes, inflammation, sleep, and heart health, in individuals at high risk for AD.
  • Testing whether certain blood pressure medications penetrate the brain and act on Alzheimer's disease biomarkers, thereby potentially reducing AD risk.
  • Testing potential racial differences in the way that blood pressure medications penetrate the brain and potentially influence AD risk, while at the same time investigating both physiological and sociological factors that may lead to these differences.
  • Understanding how sex hormones in the body and in the brain influence an individual’s risk for AD.
  • Adapting existing AD caregiver interventions to make the information more applicable to African Americans and the LGBTQ community.

To learn more about our lab, please visit our website here.

COVID-19 Serosurveillance Study Updates